Intellia Therapeutics (NTLA) CMO awarded options and RSUs in Form 4 filing

Rhea-AI Filing Summary

Intellia Therapeutics executive vice president and chief medical officer David Lebwohl reported equity awards on Common Stock and stock options. On March 1, 2026, he acquired stock options for 14,204 shares at an exercise price of $0.00 per share under a grant, award, or other acquisition.

He also acquired 9,943 shares of Common Stock at $0.00 per share through a grant of restricted stock units, each representing a contingent right to receive one share of Intellia common stock. Following these grants, his directly owned Common Stock position is 131,192 shares.

Insider Trade Summary

2 transactions reported

Mixed 2 txns

Insider Lebwohl David

Role EVP, Chief Medical Officer

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy)	14,204	$0.00	--
Grant/Award	Common Stock	9,943	$0.00	--

Holdings After Transaction: Stock Option (right to buy) — 14,204 shares (Direct); Common Stock — 131,192 shares (Direct)

Footnotes (1)

1. Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit. This option was granted on March 1, 2026 with respect to shares of Common Stock, with 33% vesting on January 1, 2027 and the remaining 67% vesting in 24 substantially equal monthly installments thereafter.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lebwohl David

(Last) (First) (Middle)

C/O INTELLIA THERAPEUTICS, INC.

40 ERIE STREET; SUITE 130

(Street)

CAMBRIDGE MA 02139

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Intellia Therapeutics, Inc. [ NTLA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	EVP, Chief Medical Officer

3. Date of Earliest Transaction (Month/Day/Year)
03/01/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock(1)	03/01/2026		A		9,943	A	$0	131,192	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$13.78	03/01/2026		A		14,204		(2)	02/29/2036	Common Stock	14,204	$0	14,204	D

Explanation of Responses:

1. Based on a grant of restricted stock units representing a contingent right to receive one share of Intellia common stock for each restricted stock unit.

2. This option was granted on March 1, 2026 with respect to shares of Common Stock, with 33% vesting on January 1, 2027 and the remaining 67% vesting in 24 substantially equal monthly installments thereafter.

	James Basta, attorney-in-fact	03/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did NTLA executive David Lebwohl report on this Form 4?

David Lebwohl reported two equity awards from Intellia Therapeutics. He received 14,204 stock options with an exercise price of $0.00 per share and 9,943 shares of Common Stock via restricted stock units granted on March 1, 2026.

How many Intellia Therapeutics (NTLA) stock options were granted to David Lebwohl?

He was granted stock options covering 14,204 shares of Intellia Common Stock. These options have an exercise price of $0.00 per share and were awarded on March 1, 2026, as a grant, award, or other acquisition transaction.

What are the vesting terms for David Lebwohl’s new NTLA stock option grant?

The option was granted on March 1, 2026, with 33% vesting on January 1, 2027. The remaining 67% vests in 24 substantially equal monthly installments after that date, according to the disclosed vesting schedule.

What does the restricted stock unit grant to David Lebwohl at Intellia involve?

The grant consists of restricted stock units representing a contingent right to receive one share of Intellia common stock for each unit. In this filing, 9,943 shares of Common Stock were acquired at $0.00 per share as part of that RSU award.

What is David Lebwohl’s role at Intellia Therapeutics (NTLA) in this Form 4?

David Lebwohl is identified as an officer of Intellia Therapeutics, serving as executive vice president and chief medical officer. The Form 4 reports equity awards granted to him in that capacity, including stock options and restricted stock units.

How many shares of Intellia Common Stock does David Lebwohl hold after these transactions?

After the reported March 1, 2026 transactions, David Lebwohl directly owns 131,192 shares of Intellia Therapeutics Common Stock. This total reflects the addition of 9,943 shares acquired through the restricted stock unit grant.